Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Ophthalmology|February 19, 2018
Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments TrialsEbenezer Daniel, Wei Pan, Gui-Shuang Ying, et al.
Aging Cell|October 9, 2021
Intraocular iron injection induces oxidative stress followed by elements of geographic atrophy and sympathetic ophthalmiaYingrui Liu, Brent A Bell, Ying Song, et al.
JAMA Ophthalmology|May 31, 2014
Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trialsGui-shuang Ying, Benjamin J Kim, Maureen G Maguire, et al.
Ophthalmology. Retina|May 19, 2020
Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy: A Randomized Clinical TrialBenjamin J Kim, Allan Hunter, Alexander J Brucker, et al.
Neurobiology of Aging|March 1, 2023
Retinal photoreceptor layer thickness has disease specificity and distinguishes predicted FTLD-Tau from biomarker-determined Alzheimer's diseaseBenjamin J Kim, Murray Grossman, Tomas S Aleman, et al.
Scientific Reports|July 2, 2025
Choroidal evaluation of FTLD-Tau and biomarker-determined Alzheimer's diseaseBenjamin J Kim, Tomas S Aleman, Katheryn A Q Cousins, et al.
Retina (Philadelphia, Pa.)|January 12, 2018
FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment TrialAkosua A Nti, Leona W Serrano, Harpal S Sandhu, et al.
Clinical Immunology (Orlando, Fla.)|April 2, 2020
Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primatesSarah Hughes, Justin Gumas, Rebecca Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2022
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant MelanomaJanice M Mehnert, Tara C Mitchell, Alexander C Huang, et al.
Pageof 6